Should it receive approval, the contraceptive pill would be marketed under the brand name Opill by Perrigo. This pill is a progestin-only contraceptive, meaning it contains only a synthetic variant of the hormone progesterone to avert pregnancy, unlike most pills which also include estrogen.
While the FDA usually adheres to the guidance of its advisory committees, it is not mandatory for them to do so.
“I feel that the risk of unintended pregnancy is lower with this approach than any of the other available contraceptive approaches that women have access to without seeing a health care provider,” said Dr. Deborah Armstrong, a professor of oncology, gynecology and obstetrics at Johns Hopkins to NPR.
The advantages include enhanced access to efficient contraception, a decrease in unplanned pregnancies and their associated risks, as well as amplified reproductive independence.